Post

New research · Hematology
Clinical rheumatology · 23h
Cohort studyClinical rheumatology · 2026

Clinical characteristics and prognosis of primary Sjögren's disease patients with hypocomplementemia: reduced C3 is independently associated with new-onset peripheral cytopenias.

Zihan Liu, Jiaqi Chen, Yan Zhang … Jing Luo
Read paper
HematologyCohort study

Lower C3 levels linked to 30% higher risk of new peripheral cytopenias.

Clinical characteristics and prognosis of primary Sjögren's disease patients with hypocomplementemia: reduced C3 is independently associated with new-onset peripheral cytopenias.

Zihan Liu et al. · Clinical rheumatology · 2026
Purpose

To investigate the clinical characteristics and prognostic significance of hypocomplementemia in patients with primary Sjögren's disease (pSjD), with a particular focus on its association with new-onset peripheral cytopenias.

Methods

This ambispective cohort study included patients with SjD treated at the China-Japan Friendship Hospital from 2016 to 2023.

n = 1013 patients
30%
Results
higher risk
increased risk of new low blood cell counts per 0.1 g/L C3 decrease
n = 1013 patients
More results

Among 1013 patients with SjD, 52.6% exhibited hypocomplementemia.

More results

At baseline, patients with hypocomplementemia had higher disease activity and a greater prevalence of immunological abnormalities, including hyper-IgG and positivity for anti-SSA, anti-SSB, and anti-Ro52 antibodies, as well as more frequent peripheral cytopenias (including leukopenia, neutropenia, lymphocytopenia, erythrocytopenia, anemia, and thrombocytopenia).

“
Conclusion · 1 of 3

Hypocomplementemia in SjD is associated with higher disease activity, immune dysregulation, and a greater prevalence of peripheral cytopenias.

Conclusion · 2 of 3

Decreased C3, but not C4, is independently associated with new-onset peripheral cytopenias, supporting further investigation of C3 as a candidate biomarker for risk stratification.

Conclusion · 3 of 3

Key Points • Hypocomplementemia is common in primary Sjögren's disease and is associated with younger age at onset, female predominance, and higher disease activity.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Study
92.3%
Share of treated patients whose lymphoma shrank or cleared after treatment
Randomized Trial
60%
Cumulative mortality was 60% with beta-glucan, reduced from 100% in untreated fish.
Cohort Study
HR 2.59
sudden kidney damage meant over twice the risk of death for CAR-T recipients
Study
30%
About 30% of peptides from multiple myeloma cell lines stimulated CD8+ T-cell responses.
AI / Informatics
C-index = 96.0%
The model accurately predicted when initial leukemia treatment would not work
Cohort Study
97.30%
The AI model correctly identified aplastic anemia or myelodysplastic syndromes 97.30% of the time.
Cohort Study
55.9% vs. 68.1%
Diabetic patients had lower major molecular response at 12 months (55.9% vs 68.1%).
Cohort Study
OR 3.8
Each additional low lab value associated with 3.8 times higher odds of Multisystem Inflammatory Syndrome in Children.